These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 380326)
61. The use of microfluorochromasia in platelet crossmatching as a means of evaluating thrombocytopenic patient sera. Stux S; Pitman T; Dubey D; Ervin T; Gazit E; Shanley K; Yunis E Transplant Proc; 1981 Mar; 13(1 Pt 2):995-7. PubMed ID: 7268903 [No Abstract] [Full Text] [Related]
62. Platelet antibodies: their detection and significance. Harmon JA; Miller WV Am J Med Technol; 1981 Oct; 47(10):797-802. PubMed ID: 7036742 [No Abstract] [Full Text] [Related]
64. Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens. Grishaber JE; Birney SM; Strauss RG Transfusion; 1993; 33(11):910-4. PubMed ID: 8259596 [TBL] [Abstract][Full Text] [Related]
65. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675 [TBL] [Abstract][Full Text] [Related]
66. Determination Thuku NW; Shikuku K; Mbugua A Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628 [TBL] [Abstract][Full Text] [Related]
67. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness]. Basire A; Picard C Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423 [TBL] [Abstract][Full Text] [Related]
68. The importance of sharing major histocompatibility complex and minor antigens between blood and graft donors in the blood transfusion effect. Peugh WN; Wood KJ; Morris PJ Transplant Proc; 1987 Feb; 19(1 Pt 1):744-5. PubMed ID: 3274861 [No Abstract] [Full Text] [Related]
69. [Role of the HL-A system in the transfusion of platelets and leukocytes]. Mannoni P; Rodet M; Bracq C Rev Fr Transfus Immunohematol; 1977 Mar; 20(1):49-55. PubMed ID: 268002 [No Abstract] [Full Text] [Related]
70. The clot: platelet transfusion. Chapman R Rocky Mt Med J; 1977; 74(3):146-50. PubMed ID: 301288 [No Abstract] [Full Text] [Related]
76. Management of the Platelet Refractory Patient. Forest SK; Hod EA Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003 [TBL] [Abstract][Full Text] [Related]
77. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial. Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788 [TBL] [Abstract][Full Text] [Related]
78. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates. Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG Transfusion; 1977; 17(6):657-61. PubMed ID: 595123 [TBL] [Abstract][Full Text] [Related]
79. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. Daly PA; Schiffer CA; Aisner J; Wiernik PH JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763 [TBL] [Abstract][Full Text] [Related]
80. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA. McVey M; Cserti-Gazdewich CM Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]